Subcutaneous RYBREVANT shows 77% overall response rate in head and neck cancer
Johnson & Johnson said the results from the Phase 1b/2 OrigAMI-4 study support the ongoing pivotal Phase 3 OrigAMI-5 study.
GetSignal Johnson & Johnson JNJ
Johnson & Johnson announced on October 25, 2026, new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study of first-line subcutaneous RYBREVANT (amivantamab) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy. The study covers patients with advanced recurrent or metastatic head and neck squamous cell carcinoma other than HPV-associated oropharyngeal squamous cell carcinoma. The company said the findings support the ongoing pivotal Phase 3 OrigAMI-5 study and expand its clinical development program for subcutaneous amivantamab in head and neck cancer.
Key facts
- Overall response rate
- 77%
- Study
- Phase 1b/2 OrigAMI-4, Cohort 5
- Treatment setting
- First-line
Source: The company's release on GlobeNewswire, October 25, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
